Therapeutic Goods (Medical Devices—Specified Articles) Instrument 2020

The instrument’s core legal mechanism is class specification: it defines whole classes of articles that are to be treated as medical devices under paragraph 41BD(1)(ab) of the Therapeutic Goods Act 1989 (s 5). The instrument does not itself set out safety standards, conformity pathways or penalties; rather it alters the set of things to which the Act’s medical-device regime applies.

Key definitional points that structure the instrument’s operation are in s 4. Several critical terms are imported from subsection 3(1) of the Act (for example, conformity assessment certificate, manufacturer, Register, medical device) and other legislative instruments (the Therapeutic Goods (Medical Devices) Regulations 2002, hereafter the MD Regulations). The instrument defines “relevant practitioner” as either a health practitioner or “other person suitably trained or qualified” who is acting on the instruction or at the request of a health practitioner (s 4). The instrument also adopts the MD Regulations’ meanings for “therapeutic cannabis vaping good”, “therapeutic vaping device” and “therapeutic vaping device accessory” (s 4), signalling that the MD Regulations supply technical definitions for vaping-related items included by Schedule 1.

Schedule 1 lists 14 specified classes. The classes are generally expressed by function and by the supplier’s stated or represented intended use rather than by chemical composition alone. Examples that illustrate the instrument’s conceptual tests include:

• Representation and intention test: many items are captured only if they are “intended, by the person under whose name the articles are or are to be supplied” to be used for a particular health purpose (see items 1, 2, 3, 3A-3E, 4-7, 8, 9, 10). The supplier’s representation or branding is therefore central to classification.

• Mode-of-action test: several items are captured only when they do not achieve their principal intended action by pharmacological, immunological or metabolic means, but instead by physical means; this appears explicitly in item 2(b) and is the central test in items 11-14 where products “achieve their principal intended action only by means of physical action” (items 11-14).

• Practitioner-use qualifier: several dental and orthopaedic materials are specified subject to their being “intended…to be used by a relevant practitioner” (items 3A-3E, 3C, 3D). That ties classification to the anticipated user and the clinical supply context, not solely to product composition.

• Software inclusion: several items explicitly include “software necessary for their proper application” (for example items 2, 3C, 3D), reflecting that software forming part of an intended medical function is treated as part of the medical device class.

• Temporal transition: items 8-14 are subject to transitional rules in s 6 if those goods were registered or listed immediately before the 2025 amendment instrument; the transitional rules defer full application of the new classing until Register inclusion or 1 January 2031, but allow dealings for the purposes of applying for conformity assessment certificates and Register inclusion (s 6(1)-(3)).

The instrument thus stitches classification to supplier-intention, represented use, mode of action and user context, and it incorporates software and components where the item is “necessary” to the device’s proper application. The instrument also interacts with the Act’s conformity assessment and Register processes by making the classes eligible for those established pathways (s 6(3)). The structure places emphasis on labelling, representation and user instructions as determinative inputs to classification. The instrument deliberately cross-references other instruments for technical definitions (the MD Regulations) and the Act for procedural regimes (Parts 4‑4 and 4‑5), so the legal meaning of many terms is supplied externally rather than within the instrument itself (s 4; s 6(3)(c)).

The instrument affects multiple actors along the supply chain and in clinical practice. Primary categories are suppliers (including manufacturers and importers), persons under whose name articles are supplied, health practitioners and “relevant practitioners”, and those who make representations about product use.

• Suppliers and manufacturers: The instrument specifies classes as medical devices where the classification depends on what the article is “intended, by the person under whose name the articles are or are to be supplied” to be used for. That language brings within scope persons who brand, market, label or otherwise place articles on the market under their name (items 1, 2, 3, 3A-3E, 4-10, 11-14). Manufacturers or entities placing goods on the market will therefore need to consider whether their representations or intended uses draw the articles into the Act’s scope.

• Importers and distributors: Because the instrument’s classificatory trigger is the supplier’s representation, importers or distributors who market or rebrand products will be affected if they present an item as suitable for a medical use (for example, as fit for use in a clinical setting) or under whose name the product is supplied. An importer who sells an article represented as suitable for surgery will fall within item 1 if the representation is made.

• Health practitioners and “relevant practitioners”: The instrument defines “relevant practitioner” as a health practitioner or another person suitably trained or qualified acting on a health practitioner’s instruction or request (s 4). Items 3A-3E and 3C-3D, which specify dental and orthopaedic materials used by a “relevant practitioner”, therefore affect dentists, dental technicians acting at a dentist’s instruction, orthotists and allied staff who manufacture devices in clinical contexts. Those practitioners will face rules applicable to supply and manufacture under the Act where their materials and articles meet the specified descriptions.

• Clinical facilities and hospitals: Hospitals and clinics that source non-sterile personal protective equipment, disinfectants, contact lens solutions, saline flush syringes and other items in Schedule 1 may find procurement and compliance obligations altered where the items fall within the specified classes (items 1, 4-6, 10).

• Makers of vaping-related products and components: Item 7 explicitly captures articles or components likely to be taken for use in manufacture of therapeutic vaping devices, therapeutic vaping device accessories or therapeutic cannabis vaping goods, including mouthpieces, coils, batteries, lights and casements, while excluding general fasteners such as bolts and screws. Because the instrument adopts the MD Regulations’ definitions for therapeutic vaping terms (s 4), any person manufacturing or supplying components that are “likely to be taken to be” for vaping device manufacture will need to consider the MD Regulations’ definitions and whether their goods fall within item 7.

• Makers of consumer goods making health claims: Items such as 3 (bedding, clothing, towels and other fabric articles represented expressly to be effective against COVID‑19) and items capturing moisturisers, dentifrices, lice treatments, and weight-loss treatments that act by physical means (items 3, 11-14) affect consumer-products businesses that make explicit health claims. If a supplier represents a towel, textile or moisturiser as effective against COVID‑19 or as effecting weight loss by physical action, those representations will pull the product into the medical-device regime.

• Regulators and compliance advisers: The Australian regulator responsible for therapeutic goods (the TGA under the Act) is the decision-maker for conformity assessment certificates and Register inclusion. The instrument’s cross-reference to Parts 4‑4 and 4‑5 of the Act (s 6(3)(c)) means regulators, compliance teams and professional advisers will be involved in applications for conformity assessment certificates and Register inclusion when products in these classes are to be handled under the Act.

The instrument therefore affects both manufacturers and downstream actors whose marketing, labeling or clinical use practices determine the “intended” use. Entities whose supply chains span rebranding, import or clinical manufacture are particularly exposed to reclassification risk. Items 8-14 carry transitional rules for goods that were registered or listed immediately before the 2025 amendment instrument, so suppliers of those goods should note that their obligations change depending on whether the goods are already registered/listed and depending on whether they seek Register inclusion or allow the transitional deferral to run to 1 January 2031 (s 6).

This instrument itself does not spell out novel obligations such as record-keeping, adverse-event reporting or civil penalties. Instead, it alters which things are subject to the Act’s existing duties and rights by designating classes of articles as medical devices (s 5). The immediate consequence is that persons dealing with items in Schedule 1 will have the duties and rights under the Therapeutic Goods Act 1989 and associated regulations that apply to medical devices.

Duties that thus become relevant include conformity assessment and Register inclusion pathways. The instrument explicitly contemplates applications for a conformity assessment certificate and applications for inclusion in the Register as a kind of medical device, and it ties the transitional treatment of certain goods (items 8-14 as inserted by the 2025 amendment instrument) to those application processes (s 6(3)(a)-(b)). The instrument also refers to Parts 4‑4 and 4‑5 of the Act in relation to conformity assessment certificates and inclusion in the Register (s 6(3)(c)). Those Parts of the Act govern procedural rights and obligations connected to conformity assessment (for example, how conformity assessment is granted or recognised) and to Register inclusion (for example, how kinds of medical devices are included in the Register). The instrument does not alter those Parts; it makes the classes specified in Schedule 1 eligible to be subject to the processes and the outcomes they create.

Key practical duties and rights implicated by that referral include:

• Duty to obtain, or the right to apply for, a conformity assessment certificate where required by the Act for a device class or kind (s 6(3)(a)). The instrument explicitly allows goods in items 8-14 to be dealt with for the purpose of such applications even while transitional deferral applies (s 6(3)(a)).

• Duty to apply for inclusion in the Register as a kind of medical device where the supplier or manufacturer wants that status, and the right to such an application under the Act (s 6(3)(b)).

• Procedural rights and obligations attached to being a registered or listed good under the Act, since s 6(1) and (2) treat previously registered or listed goods differently when items are inserted or amended by the 2025 instrument.

• Compliance duties that flow from being classified as a medical device: while the instrument does not list these, by making the classes subject to the Act it triggers whatever post‑classification obligations the Act and subordinate regulations impose (for example, labelling, safety and performance requirements, conformity assessment, adverse event reporting and other regulatory obligations found in the Act and the MD Regulations). The instrument’s s 4 notes that many of the relevant expressions (conformity assessment certificate, manufacturer, medical device, Register, registered/listed goods, supply) are defined in subsection 3(1) of the Act, underlining that rights and duties on those topics are controlled by the Act.

• Practitioner-specific responsibilities: where items are intended to be used by a “relevant practitioner” (s 4; items 3A-3E, 3C-3D), clinical users may face obligation changes in how they source, prepare or supply such materials, because the Act governs the supply of medical devices used in clinical settings.

• Transitional rights: for goods that were registered or listed immediately before commencement of the 2025 amendment instrument, s 6(2) provides a temporary exclusion from items 8-14 until Register inclusion or 1 January 2031. Concurrently, s 6(3) allows those goods to be dealt with for the purpose of applications, permitting suppliers to commence regulatory processes voluntarily.

Two definitional points are central to duty allocation. First, the “intended” use is judged by the person under whose name the articles are supplied; thus the supplier’s representations are the primary determinant of duty capture (Schedule 1 items). Second, the instrument incorporates MD Regulations’ definitions for vaping items (s 4), so duties for vaping-related articles will hinge on the MD Regulations’ terms. The instrument therefore creates duties indirectly by changing classification; the specific compliance tasks remain those set out in the Act and the MD Regulations, as referenced in s 4 and s 6(3).

The instrument itself does not create new civil or criminal penalties nor does it stipulate a new enforcement regime. It is an instrument of classification: it specifies classes of articles to be treated as medical devices under the Therapeutic Goods Act 1989 (s 5), thereby making them subject to the Act’s existing enforcement tools. The making of the instrument is authorised by subsection 41BD(2B) of the Act (s 3), which is the statutory mechanism permitting the specification of classes. Any penalties, compliance notices, or enforcement actions therefore arise under the Act and associated regulations rather than under this instrument.

The instrument explicitly references procedural parts of the Act that relate to conformity assessment certificates (Part 4‑4) and inclusion in the Register (Part 4‑5) when dealing with transitional matters for items added by the 2025 amendment instrument (s 6(3)(c)). Those Parts of the Act govern administrative processes that can lead to legally binding regulatory statuses, which in turn carry the Act’s enforcement consequences (for example, unauthorised supply of regulated medical devices may be an offence under the Act; however, the instrument itself does not set out offence clauses or penalty amounts).

Concrete enforcement implications for suppliers arise because once an article is a “medical device” under the Act, the supplier must comply with the statutory obligations for medical devices. Non‑compliance with those obligations under the Act and MD Regulations can attract enforcement mechanisms available under the Act , administrative action, injunctions, recall powers, fines or criminal sanctions , but the instrument does not itself enumerate these. To identify exact penalty amounts, compliance timeframes and enforcement tools, one must consult the Act and the MD Regulations which set out offences, civil penalties and enforcement powers that apply to regulated therapeutic goods.

The instrument does create one practical enforcement-relevant feature: it ties classification to supplier representation and intended use. Enforcement agencies will therefore assess labelling, marketing, instructions and representations when determining whether an item falls within a specified class. The transitional rules in s 6(2) provide temporary relief for certain goods (those registered or listed immediately before the 2025 amendment instrument) by deferring the application of items 8-14 until Register inclusion or until 1 January 2031, whichever is earlier. But s 6(3) allows dealing with those goods for the purpose of conformity assessment and Register applications, which means enforcement exposure can arise as soon as a supplier elects to seek regulatory recognition.

In short, the instrument is an enabling and classificatory instrument; enforcement and penalties flow from the Act’s general scheme, which remains the operative source of sanctions and remedy mechanisms. The instrument’s relevance to enforcement is therefore that it expands the set of goods to which the Act’s enforcement tools may be applied without specifying new penalties itself.

The instrument is tightly cross‑referenced to the Therapeutic Goods Act 1989 and to the Therapeutic Goods (Medical Devices) Regulations 2002, and it borrows definitions and procedural architecture from those instruments. Section 3 states the authority under which the instrument is made: subsection 41BD(2B) of the Act. Section 4 notes that a number of expressions used in the instrument are defined in subsection 3(1) of the Act , for example, conformity assessment certificate, manufacturer, medical device, Register, registered/listed goods and supply , so the instrument relies on the Act for core legal terminology. The instrument therefore interacts as an extension of the Act’s device classification scheme, not as a standalone regulatory text.

The instrument also expressly imports meanings from subordinate regulation: it adopts the MD Regulations’ meanings for “therapeutic cannabis vaping good”, “therapeutic vaping device” and “therapeutic vaping device accessory” (s 4). That means the legal treatment of vaping‑related items under Schedule 1 cannot be fully assessed without reference to the MD Regulations’ technical definitions and thresholds. Practically, this creates a layered interaction: Schedule 1 says that certain components likely to be for vaping-device manufacture are medical devices, while the MD Regulations supply the substantive definitions that determine whether a product is a “therapeutic vaping device” or accessory.

Substantive procedural interactions are signalled in s 6(3), which permits goods subject to transitional deferral to be dealt with in accordance with the amendments for the purpose of conformity assessment certificates and inclusion in the Register, and directly references Parts 4‑4 (conformity assessment certificates) and 4‑5 (Register inclusion) of the Act. Therefore, the instrument interacts with those Parts by making its specified classes eligible to follow the statutory paths set out there. The instrument does not amend Parts 4‑4 or 4‑5, but by changing what counts as a medical device it triggers the operation of those Parts for new categories of articles.

The instrument also invokes the Acts Interpretation Act 1901 principle (s 4 note referencing s 18A , grammatical forms). It notes that other grammatical forms of defined words have a corresponding meaning, citing section 18A of the Acts Interpretation Act 1901, for example to clarify that manufacturer and manufacture are treated correspondingly (s 4 note). This is a drafting-level interaction ensuring that the definitions imported from the Act and regulations function consistently across grammatical variants.

There are consequential interactions with other legal regimes that the instrument itself does not address explicitly but that arise from classification: consumer protection and product liability law, occupational health and safety regulation, import controls and customs classification, and advertising law. For example, labelling and advertising claims that trigger classification under the Schedule (representations that an article is “suitable for use in surgery” or “effective against COVID‑19”) also attract obligations under the Act; concurrently, those same claims may fall within the scope of consumer protection legislation (for example, the Australian Consumer Law) for misleading representations. The instrument does not canvass these cross‑regulatory consequences but its reliance on supplier representation as the determinative test makes those interactions likely.

Finally, the instrument’s transitional provisions reference an Amendment Instrument 2025 which inserts items 8-14 into Schedule 1 and provides a temporal deferral (s 6). That means the instrument is not legally static; its practical scope may shift depending on subordinate amendment instruments. Users must therefore track both the Act and the MD Regulations and any amendment instruments to understand fully which goods are currently captured.

The instrument as provided includes a targeted amendment history reference in s 6. Section 6 addresses application, saving and transitional provisions and explicitly applies only to therapeutic goods in items 8 to 14 of Schedule 1 “that, immediately before the commencement of the Therapeutic Goods (Medical Devices,Specified Articles) Amendment Instrument 2025, were registered goods or listed goods” (s 6(1)). That language confirms that a later Amendment Instrument in 2025 inserted or altered items 8-14 into Schedule 1 and that the present instrument contains transitional saving rules responding to that 2025 amendment (s 6).

The transitional scheme in s 6 is structured as follows:

• s 6(1) identifies the universe of goods to which the transitional saving applies: therapeutic goods falling within items 8-14 that were registered goods or listed goods immediately before commencement of the 2025 amendment instrument.

• s 6(2) states that items 8-14, “as inserted by Schedule 1 to the Therapeutic Goods (Medical Devices,Specified Articles) Amendment Instrument 2025,” do not apply to those goods until the earlier of the date the goods are included in the Register as a kind of medical device or 1 January 2031. Thus the deferral runs until one of two events: proactive regulatory inclusion or the fixed date.

• s 6(3) preserves an ability to engage the Act’s processes despite the deferral: even though the items 8-14 do not apply to those goods for that transitional period, those goods “may be dealt with in accordance with the amendments made by the Therapeutic Goods (Medical Devices,Specified Articles) Amendment Instrument 2025, including for the purposes of” applying for conformity assessment certificates, applying for inclusion in the Register, and any applicable provisions in Parts 4‑4 and 4‑5 of the Act in relation to those processes (s 6(3)(a)-(c).

This amendment history shows an explicit, deliberate policy choice: the 2025 amendment inserted new items but provided a deferred capture pathway for goods that were already registered or listed immediately before the amendment, creating an opt-in pathway for suppliers to seek regulatory conformity during the deferral window. The instrument therefore both records the insertion of items 8-14 by a 2025 amendment and establishes the temporal boundary (1 January 2031) for the transitional deferral for pre-existing registered/listed goods (s 6).

Other historical details that might exist externally (for example, draft schedules, consultation papers, earlier versions of the instrument, or prior amendments) are not contained in the text provided. The instrument itself contains no earlier amendment notes or prior version history within the text supplied beyond the explicit cross-reference to the 2025 Amendment Instrument. Practitioners should therefore treat s 6 as the operative amendment-history disclosure in this instrument, and consult the legislative database or the Federal Register of Legislation for chronological amendments, commencement dates and the text of the 2025 Amendment Instrument to see the precise insertion language for items 8-14.

The instrument contains no litigation history, judicial interpretations, or references to court decisions. It does not name any cases or judicial determinations that have construed its terms; nor does it summarise case law. The text contains only definitions, the specified classes in Schedule 1, an authority clause (s 3), and transitional provisions (s 6). Where legal disputes might arise over classification, those disputes would be resolved by courts or tribunals applying the Act and the instrument’s language, but any such adjudication is not recorded in the instrument itself.

Because the instrument’s classification tests focus heavily on supplier representation and intended use (for example, “intended, by the person under whose name the articles are or are to be supplied”), litigation on these points would likely turn on factual findings about marketing, labelling, instructions and the supplier’s state of mind. Disputes could also involve interpretation of “principal intended action” versus “assisted” action where compounds or products act partly by physical means and partly by pharmacological means (for example items 2(b) and 11-14). However, that is a speculative identification of likely dispute themes; the instrument does not record any cases.

Practitioners wanting to understand how courts might treat particular contested classifications will need to research case law under the Act and on analogous classification questions. The instrument itself provides neither precedent nor examples of judicial outcomes. Any litigation history relevant to the Act’s interpretation or to the specific Schedule items must therefore be obtained from judicial databases and is not present in the instrument text.

The instrument contains several drafting features and legal hooks that create traps for the unwary. These are factual or interpretive risks that arise from the precise wording and cross‑references in the instrument.

• Supplier representation as the determinative trigger. Many Schedule items depend on what the article is “intended, by the person under whose name the articles are or are to be supplied, to be used” for. That means marketing, labelling, packaging, instructions, user manuals and promotional material are legally decisive. A single phrase on a website or a product leaflet asserting suitability for “surgery” or “clinical use” can convert a consumer product into a medical device within the Act’s regime (see item 1 and other items generally). Suppliers who rebrand imported goods or who distribute under their own name must therefore audit marketing materials and quiet changes to avoid inadvertent capture.

• Mode-of-action ambiguity. Items 2(b) and 11-14 hinge on whether the product “achieves their principal intended action” by pharmacological, immunological or metabolic means or only by physical action. Determining the product’s “principal intended action” and the legal categorisation of “physical” v pharmacological/immunological/metabolic modes can be scientifically and legally complex. Mixed-mode products may therefore give rise to classification uncertainty.

• Practitioner-use qualifiers. Items 3A-3E and related dental/orthopaedic entries are qualified by “intended … to be used by a relevant practitioner.” The definition of “relevant practitioner” includes “other person suitably trained or qualified who is acting on the instruction, or at the request, of a health practitioner” (s 4). Supply channels that include allied health personnel, dental technicians, or in-house fabrication in clinics may therefore be treated as medical-device manufacture or supply under the Act, with attendant compliance obligations.

• Software inclusion. Several items include “software necessary for their proper application” (for example item 2, item 3C, item 3D). Suppliers that bundle decision-support or calibration software with a material or device may find the entire package regulated. DevOps/IT teams and software vendors should therefore coordinate with regulatory teams when software is sold or provided alongside the listed articles.

• Vaping definitions are outsourced. Item 7 deals with components for therapeutic vaping devices and explicitly excludes simple fasteners. However, the instrument imports the MD Regulations’ meanings for “therapeutic vaping device” and related terms (s 4). Users must therefore consult the MD Regulations to determine whether a component is “likely to be taken” for use in a therapeutic vaping device , that additional layer of cross-reference can obscure classification outcomes.

• Narrow exclusions and specific inclusions. Item 3 excludes mattresses, household furnishings, furniture or articles specified in item 1. Item 7 excludes bolts, nuts, screws, or other fasteners. Those narrow carve-outs require suppliers to check whether their article is explicitly removed or expressly included; misreading a parenthetical exclusion could lead to misclassification.

• Transitional complexity for items 8-14. For goods that were registered or listed before the 2025 amendment instrument, items 8-14 do not apply until the goods are included in the Register as a kind of medical device or until 1 January 2031, whichever occurs first (s 6(2)). That deferral might be misinterpreted as safe harbour; however s 6(3) allows such goods to be dealt with for the purposes of applying for conformity assessment certificates and Register inclusion. Suppliers must therefore plan for three pathways: voluntarily seeking conformity and registration during the deferral, waiting until they are included or until 1 January 2031, or changing representations to avoid being within the item description.

• COVID‑19 specificity. Item 3 captures bedding, clothing and towels “represented expressly to be effective against the virus that causes coronavirus disease (COVID‑19).” The expressly‑represented qualifier means general antibacterial claims will not automatically capture textiles unless COVID‑19 efficacy is explicitly asserted. Misstatements or ambiguous claims about viral protection on e‑commerce listings could however trigger classification.

• Interaction with other laws. Because the instrument’s test is supplier-centric, the same marketing claims that cause TGA capture may also trigger consumer-protection or advertising-law liability. Suppliers should consider parallel exposures, not just device regulation.

These “gotchas” are not speculative; they derive directly from the instrument’s language and its cross-references. The common thread is that representation, intended use and mode of action determine classification, and those are often operationalised through marketing and user directions , lines of activity that commercial teams frequently change without legal review.

Compliance under this instrument is achieved by treating the Schedule items as producing medical‑device regulatory status and by following the Act and the MD Regulations for devices in scope. The instrument does not list discrete compliance steps but it points to the regulatory processes that must be followed: conformity assessment certificates and inclusion in the Register, and the Act’s general device‑regulatory requirements (s 6(3)(a)-(c)). Practical compliance steps, grounded in the instrument’s structure, include the following.

1. Product inventory and mapping. Map all products, components, software and materials against Schedule 1 language. For each item, assess whether the supplier’s representation, labelling, packaging, website content, user instructions or intended user would satisfy the Schedule’s tests (for instance “intended…to be used for the prevention of the transmission of disease” in item 1, or “expressly…to be effective against the virus that causes COVID‑19” in item 3). Pay particular attention to software bundled with products and to any claims that a product is suitable for clinical or surgical use (items 1, 2, 3, 3C, 3D).

2. Marketing and representation review. Because supplier representation is the determinative trigger, review all claims (online and offline) and remove or modify claims that would classify a product as a medical device if unintended. Conversely, where a supplier elects to operate as a medical device supplier, update marketing and labelling to reflect regulatory status and obligations.

3. Legal classification decisions. For borderline products (for example those with a mix of physical and pharmacological effects, or those where the “principal intended action” is unclear), obtain regulatory legal advice or engage the regulator for classification guidance. Record the factual basis for each classification decision (labelling, instructions, internal intent) because enforcement assessments will examine those materials.

4. For dental, orthopaedic and practitioner‑used items, verify the supply pathway. Items 3A-3E and related entries are qualified by intended use by a “relevant practitioner” (s 4; Schedule 1). If the product is manufactured in-clinic or supplied under instructions from a health practitioner, treat it as a medical device and ensure the clinic/manufacturer meets relevant device supply obligations.

5. Software development controls. If software is part of a specified class (items repeatedly include “software necessary for their proper application”), integrate quality management and documentation aligned with device requirements, including validation, cybersecurity considerations and version control. Document why the software is necessary to the device’s proper application.

6. Vaping components. For components that may be “likely to be taken to be” for use in therapeutic vaping devices (item 7), consult the MD Regulations’ definitions to determine whether the component falls within “therapeutic vaping device”, “therapeutic vaping device accessory” or “therapeutic cannabis vaping good”. If uncertain, seek a regulatory classification decision.

7. Transitional pathway for items 8-14. If you supply goods that were registered or listed immediately before the 2025 amendment instrument (s 6(1)), note that items 8-14 will not apply to those goods until inclusion in the Register or 1 January 2031 (s 6(2)). Suppliers may nevertheless apply for conformity assessment certificates or Register inclusion in the interim (s 6(3)(a)-(b)). Decide whether to: (a) continue operating under the existing registered/listed status during the deferral, (b) proactively apply for conformity assessment or Register inclusion to secure regulatory clarity, or (c) change product representation to avoid the new class if that is commercially preferable.

8. Regulatory filings. Where classification indicates device status, prepare and lodge applications for conformity assessment certificates and for inclusion in the Register as required by the Act and Parts 4‑4 and 4‑5 (s 6(3)). Because the instrument references those Parts, follow the Act’s documentation, evidence, quality-management and audit requirements as set out in law and guidance.

9. Systems and processes. Implement quality management systems, post-market surveillance (including adverse event reporting), labelling and traceability systems required for medical devices under the Act. While the instrument does not specify these duties, making the articles medical devices subjects suppliers to the Act’s general device-regulatory obligations.

10. Cross‑regulatory checks. Verify that marketing and labelling changes respond not only to the Act but also to consumer-protection law, advertising law and import/export controls. Where product claims are adjusted to avoid medical-device capture, ensure those changes still comply with consumer-law obligations not to mislead.

11. Documentation and record retention. Keep evidence of the factual basis for classification choices (product design, instructions, marketing, intended user, consultation with regulators or advisers) and documentation of applications for conformity assessment and Register inclusion. That evidence will be necessary in enforcement or audit scenarios.

12. Seek regulatory guidance when needed. Where classification hinges on technical definitions in the MD Regulations (for vaping) or on scientific modes of action, seek formal or informal advice from the regulator or obtain written legal/regulatory opinion to reduce legal uncertainty.

These steps flow directly from the instrument’s structure: the focus on supplier intention and representation, the inclusion of software, the practitioner‑use qualifiers, and the transitional carve-outs for items 8-14 (s 4; Schedule 1; s 6). The instrument therefore requires compliance teams to integrate product design, marketing, clinical use patterns and regulatory pathways, and to make deliberate choices about whether to engage the medical-device regime or to alter representations to remain outside it.